TIDMAGL
RNS Number : 0018T
Angle PLC
09 October 2017
For immediate release 9 October 2017
ANGLE plc ("the Company")
PARSORTIX(TM) SYSTEM CENTRAL TO POTENTIAL NEW ANALYTICAL
PROTOCOL FOR IDENTIFYING DRUGS THAT MAY ARREST METASTASIS
Real time technique being developed to assess the impact of
cancer drugs on living circulating tumour cells harvested from
patient blood using Parsortix(TM)
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, today announces that Professor Stuart Martin from the
University of Maryland School of Medicine, USA, presented new
breakthrough research using ANGLE's Parsortix(TM) system at
Europe's leading circulating tumour cell (CTC) conference, the
Third International Advances in Circulating Tumour Cells (ACTC)
Symposium (Rhodes, Greece, 4 to 7 October 2017). During his plenary
session, Professor Martin presented results from a proof of
principle study for a real-time analytical protocol to assess drug
response on live CTCs harvested from a simple blood test using
Parsortix(TM) .
Over 90% of deaths from cancer arise from the process of
metastasis where the cancer spreads throughout the body via CTCs in
the blood causing secondary cancers. If drugs can be identified for
the patient that disable their CTCs then the metastatic spread of
the disease might be arrested or reduced.
Using the Parsortix(TM) system, Prof. Martin's laboratory
isolated CTCs from the blood of breast cancer patients and mice
transplanted with human breast tumour cells. The recovered CTCs
could then be held in place within the Parsortix(TM) cassette using
a microfluidic cell tethering technology, developed by Cellth
Systems, Inc., and imaged in real-time using high powered confocal
microscopy so as to observe the appearance of the cells and in
particular the "micro-tentacle" structures on the surface of CTCs.
These have been shown to be important to metastasis by allowing
CTCs to take root in a distant organ to establish a secondary
tumour. The entire harvesting and imaging technique could be
completed within six hours of patient blood draw.
Prof. Martin's team then proceeded to examine the effect of
changes to these micro-tentacles on individual CTCs as solutions of
different drugs were passed over them. The response varied by
patient for each drug, with (i) no impact (ii) withering and damage
to micro-tentacles, or (iii) surprisingly in some cases, growth and
potential strengthening of micro-tentacles being observed.
This proof of principle study suggests that a protocol based on
the examination, in real-time, within the Parsortix(TM) cassette,
of the effect of different drugs on CTC micro-tentacles isolated
from individual patients has potential as a personalised medicine
approach to cancer care. In principle, such an approach could allow
identification of which drugs may help to arrest metastasis in a
particular patient and which drugs will have no impact, or could
actually have a negative impact. Dr Martin's laboratory now intend
to further develop and refine this protocol for both this
application and to explore its use as a drug development tool to
identify new drugs, or already approved drugs, that appear to
impact the process of metastasis.
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"This is an unexpected new use of the Parsortix(TM) system,
which could allow major progress in identifying effective drugs for
an individual patient's cancer that may arrest or limit metastasis,
a process that is ultimately responsible for over 90% of cancer
deaths. Our vision is that a liquid biopsy using Parsortix(TM) to
harvest circulating tumour cells from a simple blood test will one
day be routinely used to support personalised medicine for all
cancer patients."
Dr Stuart Martin, Professor, Marlene and Stewart Greenebaum NCI
Comprehensive Cancer Center, University of Maryland School of
Medicine, USA commented:
"The unique ability of Parsortix(TM) to rapidly capture live
CTCs and CTC clusters from patient blood samples preserving their
metastatic CTC behaviours gives us a platform for testing new drugs
that could reduce cancer metastasis in patients. Recovering living
CTCs for immediate imaging within the Parsortix(TM) cassette really
advances our goals of testing drug responses in patient CTCs, while
allowing us to avoid the problems with growing CTCs in the
laboratory."
For further information ANGLE:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint
Broker)
Corporate Finance - Adrian
Hargrave, Simon Hicks, Kate
Bannatyne
Corporate Broking - Alice Lane,
Nikita Jain +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes +44 (0) 203 705 9318
Nigel Birks +44 (0) 203 705 9316
FTI Consulting
Simon Conway, Mo Noonan, Stephanie
Cuthbert +44 (0) 203 727 1000
Kimberly Ha (US) +1 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
This announcement contains inside information.
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world-leading liquid biopsy company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix(TM) is the subject
of granted patents in Europe, the United States, Canada, India,
China, Japan and Australia and three extensive families of patents
are being progressed worldwide. The system is based on a
microfluidic device that captures live cells based on a combination
of their size and compressibility. Parsortix(TM) has a CE Mark for
Europe and FDA authorisation is in process for the United
States.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix(TM) system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi-billion dollar clinical market. The
Parsortix(TM) system is designed to be compatible with existing
major medtech analytical platforms and to act as a companion
diagnostic for major pharma in helping to identify patients that
will benefit from a particular drug and then monitoring the drug's
effectiveness.
As well as cancer, the Parsortix(TM) technology has the
potential for deployment with several other important cell types in
the future.
ANGLE stock trades on the AIM market of the London Stock
Exchange under the ticker symbol AGL and in New York on the OTC-QX
under the ticker symbol ANPCY. For further information please
visit: www.angleplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
RESUGGMGUUPMPUR
(END) Dow Jones Newswires
October 09, 2017 02:01 ET (06:01 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024